Ji S. Lee
Suwon, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
PYCR1 drives lung cancer progression through functional interactions with EGFR and TLR signaling pathways.
Journal: Experimental & molecular medicine
Published: January 08, 2025
Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients.
Journal: Acta dermato-venereologica
Published: April 11, 2024
FFAR2 antagonizes TLR2- and TLR3-induced lung cancer progression via the inhibition of AMPK-TAK1 signaling axis for the activation of NF-κB.
Journal: Cell & bioscience
Published: February 07, 2023
β-arrestin 2 negatively regulates lung cancer progression by inhibiting the TRAF6 signaling axis for NF-κB activation and autophagy induced by TLR3 and TLR4.
Journal: Cell death & disease
Published: November 23, 2022
CRBN is downregulated in lung cancer and negatively regulates TLR2, 4 and 7 stimulation in lung cancer cells.
Journal: Clinical and translational medicine
Published: June 12, 2022
Stratifin (SFN) regulates lung cancer progression via nucleating the Vps34-BECN1-TRAF6 complex for autophagy induction.
Journal: Clinical and translational medicine
Published: March 21, 2022
USP8 regulates liver cancer progression via the inhibition of TRAF6-mediated signal for NF-κB activation and autophagy induction by TLR4.
Journal: Translational oncology
Published: October 11, 2021
USP15 negatively regulates lung cancer progression through the TRAF6-BECN1 signaling axis for autophagy induction.
Journal: Cell death & disease
Published: September 08, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026